Report cover image

Genu Recurvatum Market By Treatment Type (Surgical Treatments, Non-Surgical Treatments) , By End user (Hospitals, Orthopedic Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Publisher Allied Market Research
Published Oct 01, 2024
Length 216 Pages
SKU # ALMR19510561

Description

Genu Recurvatum Market By Treatment Type (Surgical Treatments, Non-Surgical Treatments) , By End user (Hospitals, Orthopedic Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033


The genu recurvatum market was valued at $6.5 billion in 2023, and is projected to reach $11.2 billion by 2033, growing at a CAGR of 5.6% from 2024 to 2033.

Genu recurvatum is a medical condition characterized by hyperextension of the knee joint, leading to an abnormal backward curvature while standing or walking. This condition can be caused by a variety of factors, including congenital anomalies, neuromuscular disorders, ligamentous laxity, or trauma. Genu recurvatum can range from mild to severe and often affects joint stability, gait mechanics, and overall mobility. Depending on its severity and underlying cause, it may be associated with discomfort, a higher risk of knee injuries, or long-term joint degeneration if left untreated.

The global genu recurvatum market is witnessing robust growth due to factors such as alarming rise in prevalence of neuromuscular disorders such as cerebral palsy, muscular dystrophy, and post-stroke complications, which increase the incidence of genu recurvatum, and surge in demand for therapeutic and corrective solutions. A 2022 study published by National Institutes of Health (NIH)—one of the world's foremost medical research centers—revealed that on an average the prevalence of individuals who inherited neuromuscular disorders is 3.7–4.99 per 10,000. In addition, rise in awareness of knee-related deformities and their long-term impact on mobility and quality of life has boosted early diagnosis and treatment adoption. Furthermore, increase in incidence of knee injuries due to sports, accidents, and other trauma has propelled the demand for rehabilitative therapies, including solutions for secondary conditions like genu recurvatum. Moreover, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fact that older adults are more susceptible to joint laxity and degenerative conditions, increasing the need for both conservative and surgical interventions for genu recurvatum. A 2024 study published by the World Health Organization revealed that the number of aged individuals will increase from 1 billion in 2020 to 1.4 billion by 2030. Moreover, the number of individuals aging 80 years and older is estimated to reach 426 million by 2050. However, lack of awareness and delayed diagnosis significantly restrains the market growth. Genu recurvatum often remains underdiagnosed, especially in milder cases or in underserved regions, due to a lack of awareness among patients and healthcare providers. Furthermore, high cost associated with surgical procedures, custom orthotics, and advanced rehabilitation technologies hampers the market growth. On the contrary, innovations in knee braces, prosthetics, and assistive devices tailored to manage genu recurvatum have expanded treatment options, improving patient outcomes. Such developments are expected to open new avenues for the expansion of the global market during the forecast period.

The global genu recurvatum market is segmented into treatment type, end user, and region. On the basis of treatment type, the market is categorized into human surgical treatments and non-surgical treatments. Further, the surgical treatments segment is divided into osteotomy, arthroscopy, and knee realignment surgeries. The non-surgical treatments segment is subsegmented into physical therapy, bracing & orthotics, and rehabilitation exercises. Depending on end user, it is categorized into hospitals, orthopedic clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By treatment type, the non-surgical treatments segment is expected to dominate the market from 2024 to 2033.

On the basis of end user, orthopedic clinics segment is anticipated to exhibit the highest growth during the forecast period.

Region wise, the genu recurvatum market is likely to witness strong growth in North America.

Competition Analysis

Competitive analysis and profiles of the major players in the global genu recurvatum market include Medtronic Plc, Stryker Corporation, Smith & Nephew Plc, Johnson and Johnson (DePuy Synthes), Zimmer Biomet Holdings, Inc., Globus Medical Inc, Össur, aspen medical products, and Thuasne Group, Breg, Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Key Market Segments

By Treatment Type

Surgical Treatments
Osteotomy
Arthroscopy
Knee Realignment Surgeries
Non-Surgical Treatments
Physical Therapy
Bracing and Orthotics
Rehabilitation Exercises

By End User

Hospitals
Orthopedic Clinics
Others

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

Key Market Players

medtronic PLc
Stryker Corporation
Smith & Nephew plc
Johnson and Johnson (DePuy Synthes)
Zimmer Biomet Holdings, Inc.
Globus Medical Inc
Össur
aspen medical products
Thuasne Group
Breg, Inc

Table of Contents

216 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: GENU RECURVATUM MARKET, BY TREATMENT TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Treatment Type
4.2. Surgical Treatments
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.2.5. Osteotomy
4.2.5.1. Market Size and Forecast
4.2.6. Arthroscopy
4.2.6.1. Market Size and Forecast
4.2.7. Knee Realignment Surgeries
4.2.7.1. Market Size and Forecast
4.3. Non-Surgical Treatments
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.3.5. Physical Therapy
4.3.5.1. Market Size and Forecast
4.3.6. Bracing and Orthotics
4.3.6.1. Market Size and Forecast
4.3.7. Rehabilitation Exercises
4.3.7.1. Market Size and Forecast
CHAPTER 5: GENU RECURVATUM MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Orthopedic Clinics
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: GENU RECURVATUM MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Treatment Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Genu Recurvatum Market
6.2.5.1. Market Size and Forecast, By Treatment Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Genu Recurvatum Market
6.2.6.1. Market Size and Forecast, By Treatment Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Genu Recurvatum Market
6.2.7.1. Market Size and Forecast, By Treatment Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Treatment Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. France Genu Recurvatum Market
6.3.5.1. Market Size and Forecast, By Treatment Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. Germany Genu Recurvatum Market
6.3.6.1. Market Size and Forecast, By Treatment Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. Italy Genu Recurvatum Market
6.3.7.1. Market Size and Forecast, By Treatment Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Spain Genu Recurvatum Market
6.3.8.1. Market Size and Forecast, By Treatment Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. UK Genu Recurvatum Market
6.3.9.1. Market Size and Forecast, By Treatment Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest Of Europe Genu Recurvatum Market
6.3.10.1. Market Size and Forecast, By Treatment Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Treatment Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. China Genu Recurvatum Market
6.4.5.1. Market Size and Forecast, By Treatment Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. Japan Genu Recurvatum Market
6.4.6.1. Market Size and Forecast, By Treatment Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Genu Recurvatum Market
6.4.7.1. Market Size and Forecast, By Treatment Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. South Korea Genu Recurvatum Market
6.4.8.1. Market Size and Forecast, By Treatment Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. Australia Genu Recurvatum Market
6.4.9.1. Market Size and Forecast, By Treatment Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Genu Recurvatum Market
6.4.10.1. Market Size and Forecast, By Treatment Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Treatment Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Genu Recurvatum Market
6.5.5.1. Market Size and Forecast, By Treatment Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. South Africa Genu Recurvatum Market
6.5.6.1. Market Size and Forecast, By Treatment Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. Saudi Arabia Genu Recurvatum Market
6.5.7.1. Market Size and Forecast, By Treatment Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Genu Recurvatum Market
6.5.8.1. Market Size and Forecast, By Treatment Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. Medtronic PLc
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Stryker Corporation
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. Smith And Nephew Plc
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Johnson And Johnson (DePuy Synthes)
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Zimmer Biomet Holdings, Inc.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Globus Medical Inc
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Össur
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. Aspen Medical Products
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Thuasne Group
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Breg, Inc
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 2. GENU RECURVATUM MARKET FOR SURGICAL TREATMENTS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. GENU RECURVATUM MARKET FOR NON-SURGICAL TREATMENTS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. GLOBAL GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 5. GENU RECURVATUM MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. GENU RECURVATUM MARKET FOR ORTHOPEDIC CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. GENU RECURVATUM MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. GENU RECURVATUM MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. NORTH AMERICA GENU RECURVATUM MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 10. NORTH AMERICA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 11. NORTH AMERICA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 12. U.S. GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 13. U.S. GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 14. CANADA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 15. CANADA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 16. MEXICO GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 17. MEXICO GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. EUROPE GENU RECURVATUM MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 19. EUROPE GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 20. EUROPE GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. FRANCE GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 22. FRANCE GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 23. GERMANY GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 24. GERMANY GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 25. ITALY GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 26. ITALY GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. SPAIN GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 28. SPAIN GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 29. UK GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 30. UK GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 31. REST OF EUROPE GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 32. REST OF EUROPE GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. ASIA-PACIFIC GENU RECURVATUM MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 34. ASIA-PACIFIC GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 35. ASIA-PACIFIC GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. CHINA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 37. CHINA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. JAPAN GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 39. JAPAN GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. INDIA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 41. INDIA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. SOUTH KOREA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 43. SOUTH KOREA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 44. AUSTRALIA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 45. AUSTRALIA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. REST OF ASIA-PACIFIC GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 47. REST OF ASIA-PACIFIC GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 48. LAMEA GENU RECURVATUM MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 49. LAMEA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 50. LAMEA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. BRAZIL GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 52. BRAZIL GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. SOUTH AFRICA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 54. SOUTH AFRICA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. SAUDI ARABIA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 56. SAUDI ARABIA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 57. REST OF LAMEA GENU RECURVATUM MARKET, BY TREATMENT TYPE, 2024 - 2033 ($BILLION)
TABLE 58. REST OF LAMEA GENU RECURVATUM MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. MEDTRONIC PLC: KEY EXECUTIVES
TABLE 60. MEDTRONIC PLC: COMPANY SNAPSHOT
TABLE 61. MEDTRONIC PLC: OPERATING SEGMENTS
TABLE 62. MEDTRONIC PLC: PRODUCT PORTFOLIO
TABLE 63. MEDTRONIC PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64. STRYKER CORPORATION: KEY EXECUTIVES
TABLE 65. STRYKER CORPORATION: COMPANY SNAPSHOT
TABLE 66. STRYKER CORPORATION: OPERATING SEGMENTS
TABLE 67. STRYKER CORPORATION: PRODUCT PORTFOLIO
TABLE 68. STRYKER CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. SMITH AND NEPHEW PLC: KEY EXECUTIVES
TABLE 70. SMITH AND NEPHEW PLC: COMPANY SNAPSHOT
TABLE 71. SMITH AND NEPHEW PLC: OPERATING SEGMENTS
TABLE 72. SMITH AND NEPHEW PLC: PRODUCT PORTFOLIO
TABLE 73. SMITH AND NEPHEW PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. JOHNSON AND JOHNSON (DEPUY SYNTHES) : KEY EXECUTIVES
TABLE 75. JOHNSON AND JOHNSON (DEPUY SYNTHES) : COMPANY SNAPSHOT
TABLE 76. JOHNSON AND JOHNSON (DEPUY SYNTHES) : OPERATING SEGMENTS
TABLE 77. JOHNSON AND JOHNSON (DEPUY SYNTHES) : PRODUCT PORTFOLIO
TABLE 78. JOHNSON AND JOHNSON (DEPUY SYNTHES) : KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. ZIMMER BIOMET HOLDINGS, INC.: KEY EXECUTIVES
TABLE 80. ZIMMER BIOMET HOLDINGS, INC.: COMPANY SNAPSHOT
TABLE 81. ZIMMER BIOMET HOLDINGS, INC.: OPERATING SEGMENTS
TABLE 82. ZIMMER BIOMET HOLDINGS, INC.: PRODUCT PORTFOLIO
TABLE 83. ZIMMER BIOMET HOLDINGS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. GLOBUS MEDICAL INC: KEY EXECUTIVES
TABLE 85. GLOBUS MEDICAL INC: COMPANY SNAPSHOT
TABLE 86. GLOBUS MEDICAL INC: OPERATING SEGMENTS
TABLE 87. GLOBUS MEDICAL INC: PRODUCT PORTFOLIO
TABLE 88. GLOBUS MEDICAL INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. ÖSSUR: KEY EXECUTIVES
TABLE 90. ÖSSUR: COMPANY SNAPSHOT
TABLE 91. ÖSSUR: OPERATING SEGMENTS
TABLE 92. ÖSSUR: PRODUCT PORTFOLIO
TABLE 93. ÖSSUR: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. ASPEN MEDICAL PRODUCTS: KEY EXECUTIVES
TABLE 95. ASPEN MEDICAL PRODUCTS: COMPANY SNAPSHOT
TABLE 96. ASPEN MEDICAL PRODUCTS: OPERATING SEGMENTS
TABLE 97. ASPEN MEDICAL PRODUCTS: PRODUCT PORTFOLIO
TABLE 98. ASPEN MEDICAL PRODUCTS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. THUASNE GROUP: KEY EXECUTIVES
TABLE 100. THUASNE GROUP: COMPANY SNAPSHOT
TABLE 101. THUASNE GROUP: OPERATING SEGMENTS
TABLE 102. THUASNE GROUP: PRODUCT PORTFOLIO
TABLE 103. THUASNE GROUP: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. BREG, INC: KEY EXECUTIVES
TABLE 105. BREG, INC: COMPANY SNAPSHOT
TABLE 106. BREG, INC: OPERATING SEGMENTS
TABLE 107. BREG, INC: PRODUCT PORTFOLIO
TABLE 108. BREG, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL GENU RECURVATUM MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF GENU RECURVATUM MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN GENU RECURVATUM MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALGENU RECURVATUM MARKET
FIGURE 10. GLOBAL GENU RECURVATUM MARKET SEGMENTATION, BY TREATMENT TYPE
FIGURE 11. GENU RECURVATUM MARKET FOR SURGICAL TREATMENTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. GENU RECURVATUM MARKET FOR NON-SURGICAL TREATMENTS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. GLOBAL GENU RECURVATUM MARKET SEGMENTATION, BY END USER
FIGURE 14. GENU RECURVATUM MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. GENU RECURVATUM MARKET FOR ORTHOPEDIC CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. GENU RECURVATUM MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 21. COMPETITIVE DASHBOARD
FIGURE 22. COMPETITIVE HEATMAP: GENU RECURVATUM MARKET
FIGURE 23. TOP PLAYER POSITIONING, 2023
FIGURE 24. MEDTRONIC PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 25. MEDTRONIC PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 26. MEDTRONIC PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 27. STRYKER CORPORATION: NET SALES, 2021-2023 ($BILLION)
FIGURE 28. STRYKER CORPORATION: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 29. STRYKER CORPORATION: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 30. SMITH AND NEPHEW PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 31. SMITH AND NEPHEW PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. SMITH AND NEPHEW PLC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. JOHNSON AND JOHNSON (DEPUY SYNTHES) : NET SALES, 2021-2023 ($BILLION)
FIGURE 34. JOHNSON AND JOHNSON (DEPUY SYNTHES) : REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. JOHNSON AND JOHNSON (DEPUY SYNTHES) : REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. ZIMMER BIOMET HOLDINGS, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. ZIMMER BIOMET HOLDINGS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. ZIMMER BIOMET HOLDINGS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. GLOBUS MEDICAL INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. GLOBUS MEDICAL INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. GLOBUS MEDICAL INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. ÖSSUR: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. ÖSSUR: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. ÖSSUR: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. ASPEN MEDICAL PRODUCTS: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. ASPEN MEDICAL PRODUCTS: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. ASPEN MEDICAL PRODUCTS: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. THUASNE GROUP: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. THUASNE GROUP: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. THUASNE GROUP: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. BREG, INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. BREG, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. BREG, INC: REVENUE SHARE, BY REGION, 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us